nach oben

Quality of Life Research

Erschienen in:

28.11.2016

Using EQ-5D-3L and OAB-5D to assess changes in the health-related quality of life of men with lower urinary tract symptoms associated with benign prostatic hyperplasia

verfasst von: Zalmai Hakimi, Mike Herdman, Marco Pavesi, Nancy Devlin, Jameel Nazir, Chris Hoyle, Isaac A. O. Odeyemi

Erschienen in: Quality of Life Research | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To assess changes in the health status of men with lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) using the EQ-5D-3L and OAB-5D instruments and to evaluate the sensitivity of the instruments.

Methods

Data were available from a large randomised phase III trial of men with moderate-to-severe storage and voiding LUTS/BPH (NEPTUNE). Men received a fixed-dose combination of solifenacin 6 mg plus oral controlled absorption system (OCAS™) formulation of tamsulosin (TOCAS, 0.4 mg), TOCAS monotherapy or placebo and completed the EQ-5D-3L and OAB-5D at baseline and weeks 4, 8 and 12. Analysis of covariance was used to estimate changes in EQ-5D-3L Index, EQ-VAS and OAB-5D. Changes in dimension level were summarised using the Paretian Classification of Health Change (PCHC).

Results

Improved health-related quality of life from baseline was seen in all treatment arms on EQ-5D-3L and OAB-5D at week 12, although only OAB-5D showed statistically significant differences between active treatment and placebo, both on the index score and using the PCHC approach. Effect sizes in the active treatment groups were large (>0.8) on OAB-5D but small (≈0.2) on EQ-5D-3L. EQ-5D-3L showed a very high ceiling effect (45% of men reported full health at baseline) and a substantial proportion of these men reported improvements at week 12 in several dimensions of OAB-5D.

Conclusions

A large ceiling effect on EQ-5D-3L substantially limited its sensitivity in this population. OAB-5D proved more sensitive to changes in health status and could be considered a complement to ED-5D-3L as a source of utilities for health economic modelling.

Abrams, P., Manson, J., & Kirby, M. G. (2012). Incidence and epidemiology of storage lower urinary tract symptoms. European Urological Review, 7, 50–54.

Peters, T. J., Donovan, J. L., Kay, H. E., Abrams, P., de la Rosette, J. J., Porru, D., et al. (1997). The International Continence Society “benign prostatic hyperplasia” study: The bothersomeness of urinary symptoms. Journal of Urology, 157, 885–889.CrossRefPubMed

Gravas, S., Bachmann, A., Descazeaud, A., Drake, M., Gratzke, C., Madersbacher, S., et al. (2014). Guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. Benign prostatic obstruction (BPO). Available at: http://uroweb.org/wp-content/uploads/EAU-Guidelines-Non-Neurogenic-Male-LUTS-Guidelines-2015-v2.pdf. Last Accessed 20 October 2015.

NICE CG97 Lower urinary tract symptoms: Full guideline (2010). Available at: https://www.nice.org.uk/guidance/cg97/evidence/full-guideline-245363870. Last Accessed 20 October 2015.

Garraway, W. M., Russell, E. B., Lee, R. J., Collins, G. N., McKelvie, G. B., Hehir, M., et al. (1993). Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. British Journal of General Practice, 43, 318–321.PubMedPubMedCentral

McVary, K. T. (2006). BPH: Epidemiology and comorbidities. American Journal of Managed Care, 12, S122–S128.PubMed

Schipper, H., Clinch, J. J., & Olweny, C. L. M. (1996). Quality of life studies: Definitions and conceptual issues. In B. Spilker (Ed.), Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincott-Raven Publishers.

Welch, G., Weinger, K., & Barry, M. J. (2002). Quality-of-life impact of lower urinary tract symptom severity: Results from the health professionals follow-up study. Urology, 59, 245–250.CrossRefPubMed

Coyne, K. S., Wein, A. J., Tubaro, A., Sexton, C. C., Thompson, C. L., Kopp, Z. S., et al. (2009). The burden of lower urinary tract symptoms: Evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU International, 103, 4–11.CrossRefPubMed

10.

Wein, A. J., Coyne, K. S., Tubaro, A., Sexton, C. C., Kopp, Z. S., & Aiyer, L. P. (2009). The impact of lower urinary tract symptoms on male sexual health: EpiLUTS. BJU International, 103, 33–41.CrossRefPubMed

11.

Trueman, P., Hood, S. C., Nayak, U. S., & Mrazek, M. F. (1999). Prevalence of lower urinary tract symptoms and self-reported diagnosed ‘benign prostatic hyperplasia’, and their effect on quality of life in a community-based survey of men in the UK. BJU International, 83, 410–415.CrossRefPubMed

12.

Girman, C. J., Jacobsen, S. J., Tsukamoto, T., Richard, F., Garraway, W. M., Sagnier, P. P., et al. (1998). Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology, 51, 428–436.CrossRefPubMed

13.

Boyle, P., Robertson, C., Mazzetta, C., Keech, M., Hobbs, R., Fourcade, R., et al. (2003). The relationship between lower urinary tract symptoms and health status: The UREPIK study. BJU International, 92, 575–580.CrossRefPubMed

14.

Lukacs, B., Cornu, J. N., Aout, M., Tessier, N., Hodée, C., Haab, F., et al. (2013). Management of lower urinary tract symptoms related to benign prostatic hyperplasia in real-life practice in France: A comprehensive population study. European Urology, 64, 493–501.CrossRefPubMed

15.

Drummond, M. F., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005). Methods for the economic evaluation of health care programmes (3rd ed.). Oxford: Oxford University Press.

16.

EQ-5D-3L User Guide. Version 5.1, April 2015. Available at http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/EQ-5D-3L_UserGuide_2015.pdf. Last Accessed 20 October 2015.

17.

Castro-Díaz, D., Callejo, D., Cortés, X., & Pérez, M. (2014). Study of quality of life in patients with benign prostatic hyperplasia under treatment with silodosin. Actas Urológicas Españolas, 38, 361–366.PubMed

18.

Fourcade, R. O., Lacoin, F., Rouprêt, M., Slama, A., Le Fur, C., Michel, E., et al. (2012). Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia. World Journal of Urology, 30, 419–426.CrossRefPubMed

19.

Coyne, K., Revicki, D., Hunt, T., Corey, R., Stewart, W., Bentkover, J., et al. (2002). Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-q. Quality of Life Research, 11, 563–574.CrossRefPubMed

20.

Young, T., Yang, Y., Brazier, J. E., Tsuchiya, A., & Coyne, K. (2009). The first stage of developing preference-based measures: Constructing a health-state classification using Rasch analysis. Quality of Life Research, 18, 253–265.CrossRefPubMed

21.

Desroziers, K., Aballéa, S., Maman, K., Nazir, J., Odeyemi, I., & Hakimi, Z. (2013). Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder. Health and Quality of Life Outcomes, 11, 200.CrossRefPubMedPubMedCentral

22.

van Kerrebroeck, P., Chapple, C., Drogendijk, T., Klaver, M., Sokol, R., Speakman, M., et al. (2013). Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: Efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology, 64, 1003–1012.CrossRefPubMed

23.

Electronic Medicines Compendium. Vesomni 6 mg/0.4 mg modified release tablets: Summary of product characteristics. Available at: https://www.medicines.org.uk/emc/medicine/28535. Last Accessed 20 October 2015.

24.

Chapple, C. R., Drake, M. J., van Kerrebroeck, P., Cardozo, L., Drogendijk, T., Klaver, M., et al. (2014). Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms. BJU International, 113, 696–703.CrossRefPubMed

25.

Drake, M. J., Sokol, R., Coyne, K., Hakimi, Z., Nazir, J., Dorey, J., et al. (2016). Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin oral-controlled absorption system: Results from the NEPTUNE study. BJU International, 117, 165–172.CrossRefPubMed

26.

Matza, L. S., Thompson, C. L., Krasnow, J., Brewster-Jordan, J., Zyczynski, T., & Coyne, K. S. (2005). Test-retest reliability of four questionnaires for patients with overactive bladder: The overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourology and Urodynamics, 24, 215–225.CrossRefPubMed

27.

Coyne, K. S., Matza, L. S., & Thompson, C. L. (2005). The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Quality of Life Research, 14, 849–855.CrossRefPubMed

28.

Yang, Y., Brazier, J., Tsuchiya, A., & Coyne, K. (2009). Estimating a preference-based single index from the Overactive Bladder Questionnaire. Value in Health, 12, 159–166.CrossRefPubMed

29.

Gudex, C. (2005). The descriptive system of the EuroQol instrument. In P. Kind, R. Brooks, & R. Rabin (Eds.), EQ-5D concepts and methods: A developmental history. Berlin: Springer.

30.

Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35, 1095–1108.CrossRefPubMed

31.

Walters, S. J., & Brazier, J. E. (2005). Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Quality of Life Research, 14, 1523–1532.CrossRefPubMed

32.

Hays, R. D., & Revicki, D. (2005). Reliability and validity (including responsiveness). In P. Fayers & R. Hays (Eds.), Assessing quality of life in clinical trials: Methods and practice (2nd ed.). New York: Oxford University Press.

33.

Cohen, J. (1998). Statistical power analysis for the behavioural sciences (2nd ed.). Hillsdale, NJ: L. Erlbaum Associates.

34.

Devlin, N. J., Parkin, D., & Browne, J. (2010). Patient-reported outcome measures in the NHS: New methods for analysing and reporting EQ-5D data. Health Economics, 19, 886–905.CrossRefPubMed

35.

Parkin, D., Devlin, N., & Rice, N. (2010). Statistical analysis of EQ-5D profiles: Does the use of value sets bias inference? Medical Decision Making, 30, 556–565.CrossRefPubMed

36.

Pavesi, M., Devlin, N., Hakimi, Z., Nazir, J., Herdman, M., Hoyle, C., et al. (2013). Understanding the effects on HR-QoL of treatment for overactive bladder: A detailed analysis of EQ-5D clinical trial data for mirabegron. Journal of Medical Economics, 16, 866–876.CrossRefPubMed

37.

Buckley, B.S., Lapitan, M.C., Glazener, C.M.; MAPS Trial Group. (2012). The effect of urinary incontinence on health utility and health-related quality of life in men following prostate surgery. Neurourology and Urodynamics, 31, 465–469.CrossRef

38.

Patrick, D. L., & Deyo, R. A. (1989). Generic and disease-specific measures in assessing health status and quality of life. Medical Care, 27, S217–S232.CrossRefPubMed

39.

Wiebe, S., Guyatt, G., Weaver, B., Matijevic, S., & Sidwell, C. (2003). Comparative responsiveness of generic and specific quality-of-life instruments. Journal of Clinical Epidemiology, 56, 52–60.CrossRefPubMed

40.

NICE PMG9 Guide to the methods of technology appraisal (2013). Available at: http://publications.nice.org.uk/pmg9. Last Accessed 20 October 2015.

Titel: Using EQ-5D-3L and OAB-5D to assess changes in the health-related quality of life of men with lower urinary tract symptoms associated with benign prostatic hyperplasia
verfasst von: Zalmai Hakimi
Mike Herdman
Marco Pavesi
Nancy Devlin
Jameel Nazir
Chris Hoyle
Isaac A. O. Odeyemi
Publikationsdatum: 28.11.2016
Verlag: Springer International Publishing
Erschienen in: Quality of Life Research / Ausgabe 5/2017
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-016-1460-x

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Using EQ-5D-3L and OAB-5D to assess changes in the health-related quality of life of men with lower urinary tract symptoms associated with benign prostatic hyperplasia

Abstract

Objectives

Methods

Results

Conclusions

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2017

Proxy-reported quality of life in adolescents and adults with dyskinetic cerebral palsy is associated with executive functions and cortical thickness

Contextual and individual determinants of oral health-related quality of life in older Brazilians

Health-related quality of life factors associated with completion of a study delivering lifestyle exercise intervention for endometrial cancer survivors

Quality of life, psychological characteristics, and adjustment in parents of children with Attention-Deficit/Hyperactivity Disorder

Recovery support mediates the relationship between parental warmth and quality of life among women with substance use disorders

Evaluating and establishing national norms for mental wellbeing using the short Warwick–Edinburgh Mental Well-being Scale (SWEMWBS): findings from the Health Survey for England